Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Company profile
Ticker
ASMB
Exchange
Website
CEO
Mr. Jason A. Okazaki
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
VENTRUS BIOSCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Assembly Pharmaceuticals, Inc. • Assembly Biotechnology Development (Shanghai) Co, Ltd. • Assembly Biosciences Hong Kong Limited ...
ASMB stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
23 Sep 24
S-8
Registration of securities for employees
8 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
8 Aug 24
8-K
Assembly Biosciences Announces $12.6 Million in Equity Financings
18 Jun 24
424B5
Prospectus supplement for primary offering
18 Jun 24
8-K
Departure of Directors or Certain Officers
3 Jun 24
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
8 May 24
DEFA14A
Additional proxy soliciting materials
17 Apr 24
Latest ownership filings
4
Nicole S White
5 Aug 24
4
Jason A Okazaki
5 Aug 24
4
Alexander Schornstein
8 Jul 24
SC 13D/A
Schornstein Alexander
24 Jun 24
SC 13D/A
GILEAD SCIENCES, INC.
20 Jun 24
4
Change in insider ownership
20 Jun 24
4
Lisa Johnson-Pratt
30 May 24
4
John G McHutchison
30 May 24
4
Susan Mahony
30 May 24
4
Michael Houghton
30 May 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.21 mm | 19.21 mm | 19.21 mm | 19.21 mm | 19.21 mm | 19.21 mm |
Cash burn (monthly) | (no burn) | 2.02 mm | 4.07 mm | 4.62 mm | 5.70 mm | 5.25 mm |
Cash used (since last report) | n/a | 5.92 mm | 11.90 mm | 13.52 mm | 16.68 mm | 15.35 mm |
Cash remaining | n/a | 13.29 mm | 7.31 mm | 5.68 mm | 2.53 mm | 3.86 mm |
Runway (months of cash) | n/a | 6.6 | 1.8 | 1.2 | 0.4 | 0.7 |
Institutional ownership, Q2 2024
18.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 5 |
Closed positions | 2 |
Increased positions | 10 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 15.89 bn |
Total shares | 1.18 mm |
Total puts | 0.00 |
Total calls | 48.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 468.00 k | $6.42 bn |
Vanguard | 200.46 k | $2.75 bn |
Millennium Management | 123.46 k | $1.69 bn |
BLK BlackRock | 77.23 k | $1.06 bn |
Renaissance Technologies | 54.91 k | $753.38 mm |
Geode Capital Management | 54.41 k | $746.65 mm |
Acuitas Investments | 50.00 k | $685.95 mm |
FHI Federated Hermes | 25.39 k | $348.41 mm |
Susquehanna International | 17.40 k | $238.73 mm |
Bridgeway Capital Management | 14.50 k | $198.94 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Aug 24 | Jason A Okazaki | Common Stock | Sell | Dispose S | No | No | 14.2325 | 981 | 13.96 k | 15,101 |
2 Aug 24 | Nicole S White | Common Stock | Sell | Dispose S | No | No | 14.2325 | 785 | 11.17 k | 12,068 |
5 Jul 24 | Alexander Schornstein | Common Stock | Buy | Acquire P | No | No | 12.52 | 4,438 | 55.56 k | 693,113 |
3 Jul 24 | Alexander Schornstein | Common Stock | Buy | Acquire P | No | No | 12.29 | 4,562 | 56.07 k | 688,675 |
17 Jun 24 | Gilead Sciences | Common Stock | Buy | Acquire P | No | No | 0 | 179,500 | 0.00 | 1,268,972 |
17 Jun 24 | Gilead Sciences | Warrant to purchase Common Stock Common Stock | Buy | Acquire P | No | No | 17 | 179,500 | 3.05 mm | 179,500 |
29 May 24 | Anthony E Altig | Stock Option Common Stock | Grant | Acquire A | No | No | 15.06 | 2,750 | 41.42 k | 2,750 |
News
HC Wainwright & Co. Reiterates Neutral on Assembly Biosciences
24 Sep 24
Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants
23 Sep 24
Jefferies Upgrades Assembly Biosciences to Buy, Raises Price Target to $35
20 Sep 24
Assembly Biosciences Q2 EPS $(1.98) Beats $(2.23) Estimate, Sales $8.53M Beat $5.96M Estimate
8 Aug 24
Insiders Buying American Software And 2 Other Stocks
9 Jul 24